uniQure N.V. (QURE)Healthcare | Biotechnology | Amsterdam, Netherlands | NasdaqGS
22.52 USD
+1.55
(7.392%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 22.49 -0.03 (-0.032%) ⇩ (Oct. 15, 2026, 7:54 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 7:44 a.m. EDT
The immediate outlook is precarious. Despite a massive 1000%+ surge over the last year driven by Huntington's disease hopes, the company is currently trapped by deteriorating fundamentals: negative earnings, negative free cash flow, and operating losses exceeding 8%. The recent FDA 'U-turn' on the AMT-130 trial for HD introduces significant regulatory risk that the market is pricing in heavily. The options data confirms a bearish sentiment, with traders stacking protection at levels far above the current price, anticipating a correction. While the long-term potential for a cure remains high, the balance sheet is fragile, and the path to profitability is unclear. This is a high-risk speculative play where the probability of a near-term decline outweighs the immediate upside. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.143639 |
| MSTL | 0.207669 |
| AutoETS | 0.213639 |
| AutoARIMA | 0.219326 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 19% |
| H-stat | 3.47 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 5.98 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 170.396 |
| Revenue per Share | 0.299 |
| Market Cap | 1,562,131,712 |
| Forward P/E | -7.61 |
| Beta | 1.06 |
| Website | https://www.uniqure.com |
As of Oct. 10, 2026, 7:44 a.m. EDT: Speculators are aggressively betting on a downside correction, evidenced by massive put volume and open interest at strikes significantly above the current price (e.g., 33, 36, 44, 45). While there is some call activity near the money, the overwhelming positioning suggests a fear of a sharp drop rather than a rally. The implied volatility is elevated, reflecting uncertainty following the FDA regulatory update and earnings miss.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.65044177 |
| Address1 | Paasheuvelweg 25 |
| All Time High | 82.49 |
| All Time Low | 3.73 |
| Ask | 26.71 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 2,386,250 |
| Average Daily Volume3 Month | 2,039,639 |
| Average Volume | 2,039,639 |
| Average Volume10Days | 2,386,250 |
| Beta | 1.058 |
| Bid | 21.14 |
| Bid Size | 9 |
| Board Risk | 4 |
| Book Value | 4.674 |
| City | Amsterdam |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | Netherlands |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 22.52 |
| Current Ratio | 10.01 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 22.55 |
| Day Low | 20.76 |
| Debt To Equity | 170.396 |
| Display Name | uniQure |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,328,200 |
| Earnings Call Timestamp Start | 1,785,328,200 |
| Earnings Timestamp | 1,785,328,200 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | -182,916,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.129 |
| Enterprise To Revenue | 69.835 |
| Enterprise Value | 1,303,963,648 |
| Eps Current Year | -3.43873 |
| Eps Forward | -2.9583826 |
| Eps Trailing Twelve Months | -4.26 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 40.2026 |
| Fifty Day Average Change | -17.682598 |
| Fifty Day Average Change Percent | -0.4398372 |
| Fifty Two Week Change Percent | -65.044174 |
| Fifty Two Week High | 71.5 |
| Fifty Two Week High Change | -48.98 |
| Fifty Two Week High Change Percent | -0.68503493 |
| Fifty Two Week Low | 8.73 |
| Fifty Two Week Low Change | 13.790001 |
| Fifty Two Week Low Change Percent | 1.5796107 |
| Fifty Two Week Range | 8.73 - 71.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,391,610,600,000 |
| Float Shares | 57,524,872 |
| Forward Eps | -2.9583826 |
| Forward P E | -7.612268 |
| Free Cashflow | -77,580,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 221 |
| Fullday Change | 1.5500011 |
| Fullday Change Percent | 7.3915176 |
| Fullday Price | 22.52 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -114,707,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.012610001 |
| Held Percent Institutions | 0.97843003 |
| Implied Shares Outstanding | 69,366,412 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. |
| Long Name | uniQure N.V. |
| Market | us_market |
| Market Cap | 1,562,131,712 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_171029664 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -252,208,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,966,107,777 |
| Number Of Analyst Opinions | 12 |
| Open | 21.75 |
| Operating Cashflow | -160,787,008 |
| Operating Margins | -8.72231 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Phone | 31 20 240 6000 |
| Post Market Change | -0.031801224 |
| Post Market Change Percent | -0.14121325 |
| Post Market Price | 22.4882 |
| Post Market Time | 1,792,108,453 |
| Previous Close | 20.97 |
| Price Eps Current Year | -6.5489297 |
| Price Hint | 2 |
| Price To Book | 4.8181434 |
| Price To Sales Trailing12 Months | 83.66172 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.792 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.38462 |
| Region | US |
| Regular Market Change | 1.55 |
| Regular Market Change Percent | 7.39152 |
| Regular Market Day High | 22.55 |
| Regular Market Day Low | 20.76 |
| Regular Market Day Range | 20.76 - 22.55 |
| Regular Market Open | 21.75 |
| Regular Market Previous Close | 20.97 |
| Regular Market Price | 22.52 |
| Regular Market Time | 1,792,094,400 |
| Regular Market Volume | 1,607,880 |
| Return On Assets | -0.15715 |
| Return On Equity | -1.57607 |
| Revenue Growth | 0.11 |
| Revenue Per Share | 0.299 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 69,366,412 |
| Shares Percent Shares Out | 0.12560001 |
| Shares Short | 8,715,837 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,874,417 |
| Short Name | uniQure N.V. |
| Short Percent Of Float | 0.1273 |
| Short Ratio | 2.9 |
| Source Interval | 15 |
| Symbol | QURE |
| Target High Price | 91.745476 |
| Target Low Price | 28.056835 |
| Target Mean Price | 61.32727 |
| Target Median Price | 66.908905 |
| Total Cash | 810,334,976 |
| Total Cash Per Share | 11.682 |
| Total Debt | 552,166,976 |
| Total Revenue | 18,672,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.26 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 29.655775 |
| Two Hundred Day Average Change | -7.1357746 |
| Two Hundred Day Average Change Percent | -0.24062006 |
| Type Disp | Equity |
| Volume | 1,607,880 |
| Website | https://www.uniqure.com |
| Zip | 1,105 BP |